Featured on CNBC: U.S. government begins two trials testing Eli Lilly’s coronavirus antibody drug

The trials, called ACTIV-2 and ACTIV-3, will look at U.S. drugmaker Eli Lilly’s experimental treatment known as LY-CoV555, which is being developed in partnership with Canadian biotech firm AbCellera.

Full coverage on CNBC.

PARTNERSHIP

Together we can make game-changing discoveries.